Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111546 | 0.79 | F2 (0.64) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL4432108 | 0.77 | F2 (0.77) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5124074 | 0.75 | F2 (0.75) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL8367657 | 0.74 | PKM (0.43) | F2PRSS1PRSS2PRSS3ELANE | |
| SCHEMBL4421258 | 0.74 | F2 (0.52) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5116802 | 0.74 | F2 (0.49) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5855010 | 0.73 | F2 (0.73) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5854681 | 0.73 | F2 (0.73) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL4431628 | 0.73 | F2 (0.58) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL3561181 | 0.72 | PTGDR2 (0.53) | PTGDR2AKR1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026324-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040097730-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097730-A1 | Thrombin inhibitors | F3, F2, SERPINC1 | F2 2/4885PRSS1 101/4885PRSS2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.